Mayne Pharma (MAYNF) 1.4070 $MAYNF Overview Of The

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mayne Pharma (MAYNF) 1.4070 $MAYNF

Overview Of The Pharmaceutical Market in Australia 2015
M2 - Thu Sep 24, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pzlvkm/the) has announced the addition of the "The Pharmaceutical Market: Australia" report to their offering. The country's health expenditure will continue to increase with the increasingly ageing population and the need for the government to subsidise more drugs to treat chronic, non-communicable disease. Such a rise in expenditure will attract pharmaceutical firms despite the low growth potential in the developed market. However, given the poor fiscal outlook in the general economy, we believe such a generous healthcare system will be unsustainable over the long term and the country will continue look at cost-cutting measures, negatively affecting the earnings of pharmaceutical firms. Risk/Reward Rating: In The Q11 Asia Pacific Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), while Australia's overall RRR score remains 66.2, its ranking has improved from third to second out of the 18 key markets in the region due to the decline in South Korea's RRR. Australia's affluent and increasingly ageing population, coupled with its proper legal framework, will continue to attract pharmaceutical firms to the country. However, profit growth will be limited given that it is a developed market. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Key Topics Covered: 1. SWOT 2. Political 3. Economic 4. Business Environment 5. Industry Forecast 6. Pharmaceutical Market Forecast 7. Healthcare Market Forecast 8. Prescription Drug Market Forecast 9. Patented Drug Market Forecast 10. Generic Drug Market Forecast 11. OTC Medicine Market Forecast 12. Pharmaceutical Trade Forecast 13. Other Healthcare Data 14. Key Risks To The Forecast Scenario 15. Macroeconomic Forecasts 16. Economic Analysis 17. Chinese Reform Efforts To Weigh On Export Growth 18. Consumption Growth To Slow Further 19. Residential Investment To Fall Short 20. Industry Risk Reward Ratings 21. Asia Pacific Risk/Reward Index 22. Australia Risk/Reward Index 23. Rewards 24. Risks 25. Market Overview 26. Industry Trends And Developments 27. Epidemiology 28. Regulatory Development 29. Regulatory Regime 30. OTC Switching Climate 31. Regional Regulatory Harmonisation 32. Recent Developments 33. Intellectual Property Issues 34. Trade Agreements Companies Mentioned - Alphapharm - Australian Pharmaceutical Industries - CSL - GlaxoSmithKline - Herron Pharmaceuticals - Mayne Pharma Group - Merck & Co - Sanofi - Sigma For more information visit http://www.researchandmarkets.com/research/pzlvkm/the
MRK: 58.67 (-0.49), GSK: 43.48 (-0.17)

HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma
PR Newswire - Mon May 18, 8:00AM CDT
HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited (ASX: MYX) under which Mayne Pharma will invest $2.5 million in HPPI in a private common stock and warrant financing. The closing of the financing is expected to occur within five business days.

Onychomycosis (Tinea Unguium) Therapeutics Pipeline Review 2015 - Analysis of 13 Companies & 15 Drug Profiles
M2 - Mon Mar 02, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/49c2b8/onychomycosis) has announced the addition of the "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Actavis plc - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Evolva SA - Helix BioMedix, Inc. - Mayne Pharma Group Limited - Meiji Seika Pharma Co., Ltd. - Moberg Pharma AB - NAL Pharmaceuticals Ltd. - Nihon Nohyaku Co., Ltd. - Novabiotics Ltd - Nuvo Research Inc. - Viamet Pharmaceuticals, Inc. Drug Profiles - albaconazole - AN-2718 - E-1224 - ELS-160 - EV-086 - HB-1275 - itraconazole - luliconazole - ME-1111 - NAL-3216 - NP-213 - Small Molecules for Fungal Infections - terbinafine - terbinafine - VT-1161 For more information visit http://www.researchandmarkets.com/research/49...chomycosis
ANAC: 99.06 (-0.14)

Onychomycosis Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Sat Feb 14, 1:30AM CST
The report "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) is a fungal illness of the nails. It is the most common nail disease in adults. It is spread through direct contact with the yeast. Onychomycosis is caused by thickened nail, ragged nail, unsightly nail and pain in the nail. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/onychomycosi...eport.html .
ANAC: 99.06 (-0.14)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 50

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading

Top 5 Most Recently Viewed Articles

American Atomics Welcomes New Director and Operational Experts

Updated Category News Views 236

American Atomics Welcomes a New Addition to Its Leadership Team American Atomics Inc. (the "Company") is excited to announce the addition of Mr. Henrik Mikkelsen to its Board of Directors. With over 30 years of expertise in investment banking and energy trading, Mr. Mikkelsen will significantly bolster the company's direction. His recent role as Managing Partner and CIO...

Continue Reading
Coinbase Price Target Surges: Insights from Top Analysts

Updated Category News Views 127

Analyst Predictions for Coinbase's Future In the dynamic landscape of finance, the role of expert analysts becomes paramount, especially when it comes to predicting movements in stock prices. A recent surge in forecasts suggests that Coinbase Global, Inc. (NASDAQ: COIN) could experience substantial growth in its stock value. With the price target moving from $280 to an...

Continue Reading
Insights on Ultra Clean Holdings' Upcoming Class Action Lawsuit

Updated Category News Views 192

Understanding the Class Action Lawsuit Against Ultra Clean Holdings The Gross Law Firm is here to inform investors of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) about an important class action lawsuit that is currently pending. This notice is directed towards shareholders who acquired shares of UCTT during the specified class period. The opportunity to participate in this...

Continue Reading
Logistics Automation Market Expected to Hit $85.19 Billion

Updated Category News Views 78

Growth of the Logistics Automation Market The logistics automation market is experiencing a transformative shift, with projections indicating that it will reach an impressive US$ 85.19 billion by 2030. This signifies a substantial increase from the US$ 35.21 billion recorded in 2022, with a compound annual growth rate (CAGR) of 11.7% expected over the period spanning 2022...

Continue Reading
Exploring Wynn Resorts' Recent Options Activity and Insights

Updated Category News Views 115

Understanding the Latest Trends in Wynn Resorts' Options Wynn Resorts has been capturing the attention of investors lately, particularly those who are willing to take a more aggressive approach in the marketplace. The underlying sentiment indicates strong, bullish activity surrounding Wynn Resorts (NASDAQ: WYNN). This is particularly significant for both institutional and...

Continue Reading